DeutschNewstral
Article
jdsupra.com on 2016-07-07 02:47
Federal Circuit Decides Amgen v. Apotex, Holds that 180-Day Notice of Commercial Marketing is Always Mandatory in Biosimilar Litigation
Related news
- The Ripple Effect of the Federal Circuit’s Decision in Amgen v. Apotex on Biosimilar Litigationjdsupra.com
- Apotex Accuses Amgen of Sham BPCIA Litigationjdsupra.com
- Amgen and Apotex do the Biosimilar Patent Dancejdsupra.com
- U.S. Biosimilar Litigation So Farjdsupra.com
- Court Rules that Apotex Must Give Amgen Notice Upon Biosimilar Licensurejdsupra.com
- Apotex Drops Sham Litigation Counterclaims in Neupogen and Neulasta Biosimilar Litigationjdsupra.com
- Amgen v. Apotex – what is the outcome when biosimilar applicants actually dance?jdsupra.com
- Apotex Prevails in Neulasta Biosimilar Litigation, Files for Cert on 180-Day Issuejdsupra.com
- Amgen v. Sandoz Biosimilar Litigation Update: Sandoz Follows the Patent Dance With Neulastajdsupra.com
- Biosimilar Litigation Updatejdsupra.com
- HUMIRA® Biosimilar Update -- Settlement in AbbVie v. Amgen Case Announced and AbbVie v. Boehringer Ingelheim Litigation Beginsjdsupra.com
- Amgen v. Apotex, Petition for Certiorarijdsupra.com
- Amgen v. Apotex: District Court Decides that the ’138 Patent is Not Invalid on Some Grounds; Enablement is Still an Open Issuejdsupra.com
- Amgen v. Apotex: Analysis of the Fed. Cir. Opinionjdsupra.com
- Supreme Court Denies Cert. in Apotex v. Amgenjdsupra.com
- Solicitor General Supports Cert in Amgen v. Sandoz, Supreme Court Denies Cert in Amgen v. Apotexjdsupra.com
- PAmgen asks FDA to approve biosimilar drugpacbiztimes.com
- PFDA approves Amgen biosimilar of AbbVie’s Humirapacbiztimes.com
- PFDA approves Amgen cancer treatment biosimilar Mvasipacbiztimes.com
- Briefing Complete in Appeal in Amgen v. Apotexjdsupra.com